eligibility_summary
Eligible: unresectable/metastatic HER2+ breast cancer (IHC 3+ or FISH+), after ≥2 cycles of first-line paclitaxel liposome plus anti‑HER2 therapy (mono or dual), ± capecitabine/carboplatin/gemcitabine, bone-only or multiple nodal metastases allowed, ECOG 0–2, expected survival ≥3 months. Exclude: other secondary malignancies, male or bilateral breast cancer, or brain metastases.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Drugs/interventions: paclitaxel liposome (liposomal taxane chemotherapy that stabilizes microtubules, avoids Cremophor to reduce hypersensitivity) combined with anti‑HER2 therapy: trastuzumab or biosimilar (IgG1 monoclonal antibody that blocks HER2 signaling and mediates ADCC), ± pertuzumab (mAb that inhibits HER2 dimerization), or pyrotinib (oral irreversible pan‑HER TKI), ± other chemotherapy (capecitabine, a pro‑drug of 5‑FU inhibiting thymidylate synthase, carboplatin, a DNA‑crosslinking platinum, gemcitabine, a nucleoside analog inhibiting DNA synthesis), with endocrine therapy for triple‑positive disease. Targets/pathways: HER2‑overexpressing breast cancer cells, HER family signaling (HER2/EGFR/HER3 → PI3K/AKT/MAPK), microtubules in dividing tumor cells, DNA replication/repair, immune ADCC, estrogen receptor pathway when applicable.